Urogen Pharma Announced That The Journal Of Urology Published Data From The Phase 3 Atlas Trial For Investigational Agent UGN-102 For Intravesical Solution In Patients With Low-Grade, Intermediate-risk Non-Muscle Invasive Bladder Cancer
Portfolio Pulse from Benzinga Newsdesk
Urogen Pharma has announced that The Journal of Urology has published data from the Phase 3 Atlas trial for investigational agent UGN-102. The trial showed UGN-102 demonstrated superiority to TURBT with a 55% reduction of risk for recurrence, progression or death in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.
August 08, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Urogen Pharma's Phase 3 Atlas trial for UGN-102 has shown promising results, potentially boosting the company's stock in the short term.
The positive results from the Phase 3 Atlas trial for UGN-102, published in The Journal of Urology, could increase investor confidence in Urogen Pharma. This could lead to an increase in demand for the company's stock, potentially driving up its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100